Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000870853
Ethics application status
Not yet submitted
Date submitted
2/08/2012
Date registered
16/08/2012
Date last updated
16/08/2012
Type of registration
Prospectively registered

Titles & IDs
Public title
Catheter-associated bloodstream infections in adults with cancer: A prospective randomised controlled trial.
Scientific title
A phase III randomised study to assess the risk of catheter-associated blood stream infections between the dominant and non-dominant arm in adults with cancer.
Secondary ID [1] 280961 0
Nil known
Universal Trial Number (UTN)
Trial acronym
CABSI
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Catheter-associated blood stream infection in cancer patients 287070 0
Condition category
Condition code
Cancer 287394 287394 0 0
Any cancer
Infection 287404 287404 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention is the randomisation to insert the central venous access device (CVAD) to either side of the body. The comparison is between two interventions of dominant or non-dominant side of the body.
Intervention code [1] 285399 0
Treatment: Devices
Intervention code [2] 285412 0
Prevention
Comparator / control treatment
Central line inserted on the dominant side of the body / central line inserted on the non-dominant side of the body
Control group
Active

Outcomes
Primary outcome [1] 287660 0
CA-BSI is defined according to the Australian Infection Control Association (Auricht, 2001) based on criteria from the National Nosocomial Infections Surveillance System from the CDC Atlanta, USA (Gaynes, 1996) and from the Public Health Laboratory Service of the UK (Glynn, 1997). CA-BSI are identified when: (a) the patient had a recognised pathogen isolated from one or more blood cultures (e.g. Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella species, Proteus species, Candida albicans); or (b) the patient had at least one of the following signs and symptoms within 24 hours of a positive blood culture being collected (fever > 38 degrees celsius, chills, rigors, hypotension), and at least one of the following: isolation of a common skin commensal (e.g. diptheroids, coagulase negative staphylococci, Micrococcus sp, Propionbacterium species, Bacillus species) from two or more blood culture sets drawn on separate occasions within a 48 hour period; or isolation of a common skin contaminant from a single blood culture and appropriate antimicrobial therapy is commenced. In addition to (a) and (b) above, the CVAD must have been present within 48 hours of the event and the organism must not be related to an infection at another site. When first detected, all positive blood culture results will be communicated by telephone to the treating physician by the laboratory staff and likely relationship to any intravenous line documented. In the event of multiple episodes of positive cultures during the lifespan of a single CVAD, the first episode of CA-BSI will be regarded as the single CA-BSI episode for the purposes of this study.
Timepoint [1] 287660 0
The primary endpoint is the CA-BSI rate defined as the number of CA-BSI divided by the number of central line days during the study period, multiplied by 1000. . Patients will continue on study until development of CA-BSI, removal of CVAD or 3 months after the last patient is enrolled.
Secondary outcome [1] 298593 0
A secondary hypothesis is that insertion of CVAD into the non-dominant side of haematology-oncology patients will reduce the risk of catheter related bloodstream infection (CR-BSI) compared to insertion of CVAD into the dominant side. CR-BSI (Mermel, 2009) is defined as per CA-BSI but with additional isolation of the same organism from culture of the CVAD tip (roll tip method (Maki, 1977)) or growth of microbes from a blood sample drawn from a catheter hub at least 2 h before microbial growth is detected in a blood sample obtained from a peripheral vein (differential time to positivity criteria) (Mermel, 2009).
Timepoint [1] 298593 0
Catheter-related blood stream infection (CR-BSI) rate: defined as the number of CR-BSI divided by the number of central line days during the study period, multiplied by 1000. Patients will continue on study until development of CA-BSI, removal of CVAD or 3 months after the last patient is enrolled

Eligibility
Key inclusion criteria
1. Provision of informed consent
2. Inpatients or outpatients with cancer who need to have a CVAD inserted
Minimum age
15 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Contraindication to CVAD insertion on one side of the body. This may include:
* patients with breast cancer where there is a preference to insert CVADs in a particular side
* prior line related thrombosis where there is a preference to insert CVADs in a particular side
* prior difficult line insertion where there is a preference to insert CVADs in a particular side
* any other medical reason where the patient’s physician or interventional radiologist believes that insertion on one side is contraindicated

2. Implantable ports will not be included in the study
3. Peripheral venous catheters are excluded

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be those in whom the decision has been made that they require a central line, who have consented
to have that line inserted, and who can have a line inserted on either side of the body. Participants will then have the study explained to them and after having any questions answered will be asked to give informed consent to having their line inserted on the dominant or non-dominant side of the body as determined by a randomisation process.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Patients consenting to the study will be randomly allocated to either dominant or non-dominant-side CVAD insertion. Randomisation will be performed using a series of sealed opaque envelopes. Trained nursing staff accessing the computer will need to input all relevant patient information before the computer can complete the randomisation procedure and allocate treatment. Due to the large sample size stratification will not be required prior to randomisation (Kernan, 1999). Any chance imbalances that do occur in important subgroups will be accounted for at the analysis stage using post-stratification. There will be three hospital departments where insertion of CVADs is performed: the Radiology Department at Princess Alexandra Hospital, the Radiology Department at Royal Brisbane and Women's Hospital and the Infectious Disease Department at Royal Brisbane and Women's Hospital.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
A power analysis based on 80% power and 5% level of significance shows that 1250 lines will be required to show a 60% relative difference in the infection rate in the two treatment arms. This calculation assumes a Cox proportional hazards regression model and event rate of 11.4%, hence 143 events are expected. Based on the line insertion rate from the Princess Alexandra Hospital Haematology-Oncology Unit observational study it would take three and a half years to accumulate 1250 lines. In addition it is expected that a proportion of patients will not consent or will not be eligible to be involved in the proposed RCT. With two sites it is envisaged that it will take approximately two years to recruit sufficient patients into the study and that follow up will continue for up to a further three months after recruitment has stopped (CA-BSI is rare after a CVAD has been inserted for longer than 3 months). We plan to have an interim analysis at the halfway point in the trial so that, among other things, we can check the assumptions of our power analysis to ensure we will have sufficient numbers to answer the primary study question.
Phase
Not Applicable
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/09/2012
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
1250
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment postcode(s) [1] 5578 0
4102
Recruitment postcode(s) [2] 5579 0
4069

Funding & Sponsors
Funding source category [1] 285744 0
Charities/Societies/Foundations
Name [1] 285744 0
Cancer Council Queensland
Country [1] 285744 0
Australia
Primary sponsor type
Hospital
Name
Metro South Hospital and Health Service
Address
Princess Alexandra Hospital
Ipswich Road
Woolloongabba QLD 4102
Country
Australia
Secondary sponsor category [1] 284581 0
Hospital
Name [1] 284581 0
Metro North Hospital and Health Service
Address [1] 284581 0
Royal Brisbane and Women's Hospital
Cnr Butterfield St and Bowen Bridge Rd
Herston QLD 4029
Country [1] 284581 0
Australia

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 287749 0
Metro South Health Human Research Ethics Committee
Ethics committee address [1] 287749 0
Ethics committee country [1] 287749 0
Australia
Date submitted for ethics approval [1] 287749 0
01/05/2012
Approval date [1] 287749 0
Ethics approval number [1] 287749 0
HREC/12/QPAH/163

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34528 0
Address 34528 0
Country 34528 0
Phone 34528 0
Fax 34528 0
Email 34528 0
Contact person for public queries
Name 17775 0
Adam Stoneley
Address 17775 0
Cancer Trials Unit
Princess Alexandra Hospital
Ipswich Road
Woolloongabbaa QLD 4102
Country 17775 0
Australia
Phone 17775 0
+61 7 3176 5054
Fax 17775 0
+61 7 3176 2252
Email 17775 0
pah_cancer_trials@health.qld.gov.au
Contact person for scientific queries
Name 8703 0
Dr Peter Mollee
Address 8703 0
Haematology Department
Princess Alexandra Hospital
Ipswich Road
Woolloongabbaa QLD 4102
Country 8703 0
Australia
Phone 8703 0
+61 7 3176 6379
Fax 8703 0
Email 8703 0
peter_mollee@health.qld.gov.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.